Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VCTX210A unit · 1 trial · 7 indications
| Arm | Type | Description |
|---|---|---|
| VCTX210A combination product | EXPERIMENTAL | Up to seven (7) units will be implanted |
| Name | Type | Description |
|---|---|---|
| VCTX210A unit | COMBINATION_PRODUCT | CRISPR-Cas9 genetically modified PEC210A cells loaded into a delivery device |
Inclusion Criteria * Diagnosis of T1D for a minimum of 5 years * Stable, optimized diabetic regimen for at least 3 months prior to enrollment Exclusion Criteria * Medical history of islet cell, kidney, and/or pancreas transplant * Occurrence of 2 or more severe, unexplained hypoglycemic events wi...
VCTX210A is an investigational combination product being studied for the treatment of type 1 diabetes mellitus. It is a small molecule therapy developed for patients with this condition, and it is currently in Phase 1 clinical development.
VCTX210A is being developed by CRISPR Therapeutics AG, a biopharmaceutical company traded on the stock exchange under the ticker symbol CRSP. The company is conducting clinical research on this investigational therapy for type 1 diabetes.
VCTX210A is in Phase 1 clinical development. It is an investigational therapy and has not been approved by regulatory authorities. One Phase 1 clinical trial has been completed to evaluate its safety and tolerability in patients with type 1 diabetes.
VCTX210A has one completed clinical trial registered as NCT05210530. This was an open-label, first-in-human study evaluating the safety and tolerability of the VCTX210A combination product in subjects with type 1 diabetes. The trial enrolled 7 participants in Canada.
VCTX210A is a unique investigational combination product developed by CRISPR Therapeutics AG. No alternative names for this therapy have been reported in clinical trial registrations. It is being studied specifically for type 1 diabetes mellitus.